newsfilter
← Latest News
Business Wire·

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune